HSD17B13 inhibitors (Enanta Pharmaceuticals)

N/A

Report date: 2025/03/20 15:48:07
NME

Base Information

Drug NameHSD17B13 inhibitors (Enanta Pharmaceuticals)
Drug Alias Name17 beta hydroxysteroid dehydrogenase 13 inhibitors (Enanta Pharmaceuticals)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Action17-beta-hydroxysteroid dehydrogenase 13 inhibitors
Targets17-beta-hydroxysteroid dehydrogenase 13
Therapy Area/IndicationsHepatitis, Autoimmune
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEnanta Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesEnanta Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsHepatitis, Autoimmune
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A